Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.50 |
| ▸ | CASR | P41180 | 2/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4390020 | 0.92 | PIK3CA (0.48) | EPHX2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL2477122 | 0.88 | HDAC1 (0.56) | EPHX2HDAC1CASRHDAC3PIK3CA | |
| SCHEMBL4394265 | 0.87 | HDAC3 (0.49) | EPHX2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL2476882 | 0.86 | HDAC3 (0.51) | EPHX2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL2473979 | 0.86 | HDAC1 (0.47) | EPHX2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL2473928 | 0.86 | HDAC1 (0.47) | EPHX2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL4392742 | 0.85 | HDAC1 (0.56) | EPHX2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL4396311 | 0.85 | HDAC1 (0.50) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL2478730 | 0.85 | HDAC1 (0.49) | EPHX2HDAC1CASRHDAC3HDAC4 | |
| SCHEMBL4391455 | 0.84 | HDAC1 (0.46) | HDAC1HDAC3HDAC4HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076332-B2 | N- (2-aminophenyl) benzamide derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-12-13 | — | — | US | disclosed |
| US-20090306077-A1 | NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306077-A1 | NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE | UACA, SLC14A1, ARG2 | EPHX2 3775/4885HDAC1 200/4885CASR 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.